Cystic Fibrosis Research
Cystic fibrosis (CF) is a common inherited disease that mostly affects the lungs and airways of a sufferer. One of the main pathological characteristics of CF is the failure of airway defence against bacterial infection, leading to frequent chest infection and progressive lung damage.
Cystic Fibrosis Research Products Targets
Products for Cystic Fibrosis Research - Page 7
- Cat.No. Product Name Information/Activity
-
BCN1808
Lavendustin A
Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of tyrosine kinase, with an IC50 of 11 ng/mL for EGFR-associated tyrosine kinase. It suppresses VEGF-induced angiogenesis and blocks the induction of LTPGABA-A.
-
BCC6702
Methyl 2,5-dihydroxycinnamate
63177-57-1
-
BCC7434
PD 158780
PD158780 is a potent EGFR family inhibitor with IC50s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.
-
BCC7486
PP 3
5334-30-5
-
BCC4513
Mubritinib (TAK 165)
Mubritinib (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM.
-
BCC6703
Tyrphostin B44, (-) enantiomer
133550-32-0
-
BCC6704
Tyrphostin B44, (+) enantiomer
133550-37-5
-
BCC2202
WHI-P154
WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC50s of 4 nM and 1.8 μM, respectively.
-
BCC7576
BAY-u 9773
Dual CysLT<sub>1</sub> and CysLT<sub>2</sub> antagonist
-
BCC7244
Cinalukast
128312-51-6
